[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL113403A - Amid of Delta-Amino-Gamma-Hydroxy-Omega-Aryl Alkenoic Acid - Google Patents

Amid of Delta-Amino-Gamma-Hydroxy-Omega-Aryl Alkenoic Acid

Info

Publication number
IL113403A
IL113403A IL11340395A IL11340395A IL113403A IL 113403 A IL113403 A IL 113403A IL 11340395 A IL11340395 A IL 11340395A IL 11340395 A IL11340395 A IL 11340395A IL 113403 A IL113403 A IL 113403A
Authority
IL
Israel
Prior art keywords
hydroxy
lower alkyl
alkoxy
lower alkoxy
amino
Prior art date
Application number
IL11340395A
Other languages
English (en)
Hebrew (he)
Other versions
IL113403A0 (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4204102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL113403(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL113403A0 publication Critical patent/IL113403A0/xx
Publication of IL113403A publication Critical patent/IL113403A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/11—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton
    • C07C255/13—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
IL11340395A 1994-04-18 1995-04-17 Amid of Delta-Amino-Gamma-Hydroxy-Omega-Aryl Alkenoic Acid IL113403A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH116994 1994-04-18

Publications (2)

Publication Number Publication Date
IL113403A0 IL113403A0 (en) 1995-07-31
IL113403A true IL113403A (en) 2001-07-24

Family

ID=4204102

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11340395A IL113403A (en) 1994-04-18 1995-04-17 Amid of Delta-Amino-Gamma-Hydroxy-Omega-Aryl Alkenoic Acid

Country Status (27)

Country Link
US (5) US5559111A (el)
EP (1) EP0678503B1 (el)
JP (1) JP3240322B2 (el)
KR (1) KR100353779B1 (el)
CN (2) CN1153759C (el)
AT (1) ATE183997T1 (el)
AU (1) AU699616B2 (el)
BR (1) BR1100656A (el)
CA (1) CA2147056C (el)
CY (4) CY2208B1 (el)
CZ (1) CZ287935B6 (el)
DE (4) DE59506707D1 (el)
DK (1) DK0678503T3 (el)
ES (1) ES2137478T3 (el)
FI (1) FI118336B (el)
GR (1) GR3031997T3 (el)
HK (1) HK1070881A1 (el)
HU (2) HU226860B1 (el)
IL (1) IL113403A (el)
LU (2) LU91373I2 (el)
MY (1) MY119161A (el)
NL (2) NL300296I2 (el)
NO (4) NO310410B1 (el)
NZ (1) NZ270936A (el)
RU (1) RU95105970A (el)
TW (2) TW366341B (el)
ZA (3) ZA953051B (el)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4408534A1 (de) * 1994-03-14 1995-09-28 Hoechst Ag Substituierte N-Ethyl-Glycinderivate zur Herstellung von PNA und PNA-/DNA-Hybriden
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
EP0716077A1 (de) * 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
US6465650B1 (en) 1995-03-13 2002-10-15 Aventis Pharma Deutschland Gmbh Substituted N-ethylglycine derivatives for preparing PNA and PNA/DNA hybrids
ES2216338T3 (es) * 1997-12-16 2004-10-16 Warner-Lambert Company Llc Aminas novedosas como agentes farmaceuticos.
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7354894B2 (en) * 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6833460B2 (en) * 1999-06-18 2004-12-21 E. I. Du Pont De Nemours And Company Preparation and use of gamma-butyrolactones as cross-linking agents
US6423850B1 (en) 1999-06-18 2002-07-23 E.I. Du Pont De Nemours And Company Preparation and use of gamma-butyrolactones as cross-linking agents
AU5518400A (en) * 1999-07-29 2001-02-19 Speedel Pharma Ag Production of n-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides
BR0112128A (pt) * 2000-07-03 2003-05-13 Speedel Pharma Ag Processo para a preparação de (r)-2-alquil-3-fenil-1-propanóis
BR0112362B1 (pt) 2000-07-05 2013-12-31 Processo para a preparação de octanoil amidas substituídas e compostos intermediários
US6800769B2 (en) * 2000-07-25 2004-10-05 Speedel Pharma Ag Process for the preparation of substituted octanoyl amides
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
EP1215201B1 (en) * 2000-12-14 2006-10-18 Speedel Pharma AG Process for the preparation of aryloctanoyl amides
JP3440082B2 (ja) 2001-02-19 2003-08-25 科学技術振興事業団 電気自動車用インホイールモーター
CA2445014C (en) 2001-05-15 2011-10-11 Speedel Pharma Ag Process for the preparation of substituted carboxylic acid esters by enzymatic hydrolysis
JP2004535424A (ja) * 2001-06-11 2004-11-25 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病の治療に有用な置換アミノアルコール
WO2003035046A2 (en) * 2001-10-18 2003-05-01 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
US20050101638A1 (en) * 2002-11-08 2005-05-12 Webb Randy L. Combination of organic compounds
CN1655819A (zh) * 2002-05-17 2005-08-17 诺瓦提斯公司 包含肾素抑制剂、钙通道阻断剂和利尿药的药物组合物
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
WO2003103652A1 (en) * 2002-06-11 2003-12-18 Elan Pharmaceuticals, Inc. METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES
US20060154926A1 (en) * 2002-06-11 2006-07-13 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease using aryl alkanoic acid amides
KR20050037585A (ko) * 2002-08-23 2005-04-22 카이론 코포레이션 벤지미다졸 퀴놀리논 및 그들의 사용
US7049469B2 (en) 2002-10-24 2006-05-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing (R)-salbutamol
PE20040762A1 (es) * 2002-11-27 2004-11-06 Elan Pharm Inc Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer
US20040266743A1 (en) * 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
MXPA06002188A (es) * 2003-08-25 2006-04-27 Warner Lambert Co Nuevos compuestos antimicrobianos de ariloxazolidinona.
CA2600973C (en) * 2003-11-26 2012-08-07 Novartis Ag .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
PE20050596A1 (es) * 2003-12-19 2005-10-18 Novartis Ag Microemulsion que comprende un inhibidor renina
US20080234285A1 (en) * 2004-01-22 2008-09-25 David Louis Feldman Combination of Organic Compounds
ES2357585T3 (es) * 2004-01-23 2011-04-27 Novartis Ag Derivados de aminoalcoholes y su actividad como inhibidores de la renina.
PL1735270T3 (pl) * 2004-01-23 2010-12-31 Novartis Ag Dwuaminoalkohole i ich zastosowanie jako inhibitorów reniny
MY144477A (en) * 2004-03-17 2011-09-30 Novartis Ag Galenic formulations of organic compounds
US20080161321A1 (en) 2004-03-17 2008-07-03 David Louis Feldman Use of Renin Inhibitors in Therapy
US20070191487A1 (en) * 2004-03-17 2007-08-16 Rigassi-Dietrich Petra G Galenic formulations of organic compounds
BRPI0508961A (pt) * 2004-03-19 2007-08-14 Speedel Experimenta Ag derivados de 5-amino-4-hidróxi-7-(1h-indolmetil)-8-metilnonamida como inibidores de renina para o tratamento de hipertensão
CN1934082A (zh) * 2004-03-19 2007-03-21 斯皮德尔实验股份公司 有机化合物
WO2005095876A1 (en) 2004-04-01 2005-10-13 Cucumber Limited Delivery and storage of goods
GB0419361D0 (en) 2004-08-31 2004-10-06 Novartis Ag Organic compounds
US20080085914A1 (en) 2004-10-08 2008-04-10 David Louis Feldman Use Of Organic Compounds
TW200633983A (en) * 2004-12-10 2006-10-01 Speedel Experimenta Ag 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-nonanamides
TW200631929A (en) 2004-12-10 2006-09-16 Speedel Experimenta Ag ω -phenyloctanamides
EP1844002A1 (en) * 2005-02-02 2007-10-17 Vitae Pharmaceuticals, Inc. 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors
BRPI0609158A2 (pt) * 2005-03-11 2010-02-23 Speedel Experimenta Ag alcanamidas substituìdas heterocìclicas úteis como inibidores de renina
CN101171230A (zh) * 2005-03-11 2008-04-30 斯皮德尔实验股份公司 用作肾素抑制剂的杂环取代的链烷酰胺
DE502006005580D1 (de) * 2005-03-17 2010-01-21 Basf Se Verfahren zur herstellung von optisch aktiven 3-phenylpropionsäurederivaten und folgeprodukte davon
GB0511686D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
WO2007006532A1 (en) 2005-07-11 2007-01-18 Novartis Ag New pyrocatechin derivatives
US20070021413A1 (en) 2005-07-20 2007-01-25 Peter Herold Diamino alcohols as therapeutic compounds
AU2006272348B2 (en) 2005-07-22 2011-06-16 Merck Frosst Canada Ltd Renin inhibitors
CN101262864A (zh) * 2005-09-17 2008-09-10 斯皮德尔实验股份公司 饱和o-杂环取代的烷酰胺
CA2622082A1 (en) 2005-09-17 2007-03-22 Speedel Experimenta Ag 5-amino-4-hydroxy-7- (imidazo [1,2-a] pyridin-6- ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension
EP1764098A1 (en) * 2005-09-17 2007-03-21 Speedel Experimenta AG Diaminoalcohols derivatives for the treatment of Alzheimer, malaria, HIV
GB0519764D0 (en) 2005-09-28 2005-11-09 Novartis Ag Organic compounds
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds
JP2009514809A (ja) * 2005-10-18 2009-04-09 ニコックス エス エイ レニン阻害剤のニトロ誘導体
AU2006304836A1 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
GB2431649A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431645A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431642A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431646A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431648A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
DE102005052195A1 (de) 2005-10-28 2007-05-03 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von chiralen Octensäurederivaten
TW200804241A (en) * 2006-02-24 2008-01-16 Novartis Ag New salt
GB0605688D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
US20100298328A1 (en) * 2006-03-31 2010-11-25 Vitae Pharmaceuticals, Inc 1-Heterocyclylamino-2-Hydroxy-3-Amino-Omega-Arylalkanes
US8084485B2 (en) * 2006-03-31 2011-12-27 Vitae Pharmaceuticals, Inc. 6-(aminoalkyl)indazoles
RU2008143055A (ru) * 2006-04-03 2010-05-10 Новартис АГ (CH) Ингибиторы ренина, предназначенные для гипертензии
ATE549322T1 (de) 2006-06-23 2012-03-15 Daiichi Sankyo Co Ltd Cyclische aminverbindung
TW200815324A (en) * 2006-06-23 2008-04-01 Daiichi Sankyo Co Ltd Straight chain amine compound
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
CA2657258A1 (en) 2006-07-20 2008-01-24 Novartis Ag Amino-piperidine derivatives as cetp inhibitors
EP1911762A1 (en) 2006-10-04 2008-04-16 Speedel Experimenta AG Amino alcohols and their use as renin inhibitors
AU2007323465B2 (en) * 2006-11-07 2011-08-04 Novartis Ag Crystalline forms of aliskiren hemifumarate
CN101528672A (zh) * 2006-11-09 2009-09-09 诺瓦提斯公司 阿利吉仑乳清酸盐
EP1938812A1 (en) * 2006-12-22 2008-07-02 Speedel Pharma AG Pharmaceutical composition using aliskiren and avosentan
EP1958666A1 (en) 2007-02-13 2008-08-20 Speedel Experimenta AG Heterocyclic-substituted alkanamides as therapeutic compounds
WO2008113835A1 (en) * 2007-03-21 2008-09-25 Novartis Ag Process for preparing (r or s)-5-{1-azido-3-[6-methoxy-5-(3-methoxy-propoxy)-pyridin-3-ylmethyl]-4-methyl-pentyl}-3-alkyl-dihydro-furan-2-one
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
WO2008119804A1 (en) * 2007-04-03 2008-10-09 Novartis Ag New methods
US8088954B2 (en) 2007-07-11 2012-01-03 Dsm Ip Assets B.V. Preparation of a saturated aldehyde
US20090076062A1 (en) * 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
US20090082458A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched aliskiren
CA2697229A1 (en) 2007-09-28 2009-04-02 Novartis Ag Galenical formulations of organic compounds
DE102007049039A1 (de) 2007-10-11 2009-04-16 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von 8-Hydrazino-8-Aryl-Octanoylderivaten und deren Verwendung
EP2463282B1 (en) 2007-11-05 2013-08-07 Novartis AG 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
JP2011503185A (ja) 2007-11-13 2011-01-27 テバ ファーマシューティカル インダストリーズ リミティド ヘミフマル酸アリスキレンの多形形態及びその調製プロセス
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
EP2404901B1 (en) 2007-12-03 2013-05-22 Novartis AG 1,2-Disubstituted 4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
EP2075244A1 (en) 2007-12-24 2009-07-01 DSMIP Assets B.V. New route to building block for making renin inhibitors
EP2255796A2 (en) 2008-02-22 2010-12-01 HanAll Biopharma Co., Ltd. Pharmaceutical preparation
EP2275093A2 (en) 2008-04-10 2011-01-19 HanAll Biopharma Co., Ltd. Pharmaceutical formulation
CA2724746A1 (en) * 2008-05-23 2009-11-26 Teva Pharmaceuticals Industries Ltd. Aliskiren monofumarate and processes for preparation thereof
WO2009149344A2 (en) * 2008-06-06 2009-12-10 Teva Pharmaceutical Industries Ltd. Solid states of aliskiren free base
EP2143425A1 (de) 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
WO2010024772A1 (en) * 2008-08-29 2010-03-04 Medivir Ab Aspartyl protease inhibitors
EP2163245A1 (en) 2008-09-10 2010-03-17 Novartis Ag Renin inhibitors for the treatment of psoriasis
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
RU2535090C2 (ru) 2009-01-28 2014-12-10 Новартис Аг Галеновы препараты органических соединений
WO2010089105A2 (en) 2009-02-05 2010-08-12 Krka, Tovarna Zdravil, D.D., Novo Mesto Moisture-activated granulation process
CA2724152A1 (en) 2009-02-05 2010-08-12 Teva Pharmaceutical Industries Ltd. Solid state forms of aliskiren compounds
BRPI1009131A2 (pt) 2009-03-20 2016-03-01 Novartis Ag composição farmacêutica compreendendo aliscireno
MX2011009846A (es) 2009-03-20 2011-09-29 Novartis Ag Formulaciones galenicas de una combinacion de dosis fija de valsartan y alisquireno.
WO2010112482A1 (en) 2009-04-01 2010-10-07 Lek Pharmaceuticals D.D. A process for dimethylation of active methylene groups
WO2011019789A1 (en) 2009-08-11 2011-02-17 Novartis Ag The ring opening of lactones and lactams
WO2011028919A2 (en) 2009-09-03 2011-03-10 Teva Pharmaceutical Industries Ltd. Solid forms of aliskiren hemifumarate and processes for preparation thereof
UA108742C2 (uk) 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
WO2011048523A1 (en) * 2009-10-21 2011-04-28 CarboDesign LLC Process for the manufacture of enantiomerically pure aryloctanoic acids as aliskiren
US8203005B2 (en) * 2009-10-29 2012-06-19 Carbo Design Llc Manufacturing process for enantiomerically pure 8-aryloctanoic acids as Aliskiren
KR20120130078A (ko) * 2009-11-09 2012-11-28 메디비르 아베 신규한 1,3-옥사졸리딘 화합물 및 이의 레닌 억제제로서의 용도
US20110113995A1 (en) * 2009-11-13 2011-05-19 Lindsay Corporation Method and apparatus for planting and irrigation
US20110137047A1 (en) * 2009-12-07 2011-06-09 CarboDesign LLC Process for enantiomerically pure 8-Aryloctanoic acids as Aliskiren
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
CN101774986B (zh) 2010-01-06 2012-03-28 浙江天宇药业股份有限公司 一种制备阿利克伦及其中间体的方法
CN102140068B (zh) * 2010-01-30 2015-03-11 浙江华海药业股份有限公司 阿利吉仑中间体3-氨基-2,2-二甲基丙酰胺的制备方法
EP2523934A1 (en) * 2010-02-10 2012-11-21 Ratiopharm GmbH Salts of aliskiren
TW201136582A (en) 2010-03-16 2011-11-01 Novartis Ag Improved pharmaceutical compositions of aliskiren and methods of delivery
TR201002256A1 (tr) 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
EP2382967A1 (de) 2010-04-21 2011-11-02 ratiopharm GmbH Aliskiren in Form einer festen Dispersion
EP2382969A1 (en) 2010-04-30 2011-11-02 Sanovel Ilac Sanayi ve Ticaret A.S. Multicoated Aliskiren formulations
CN102241650B (zh) * 2010-05-14 2014-05-07 浙江九洲药业股份有限公司 用于制备阿立克仑的中间体化合物及相关制备方法
IT1400961B1 (it) * 2010-06-04 2013-07-05 Chemo Iberica Sa Processo per la produzione di aliskiren
IT1402925B1 (it) * 2010-12-10 2013-09-27 Chemo Iberica Sa Processo per la produzione di aliskiren
TW201202178A (en) 2010-06-04 2012-01-16 Chemo Iberica Sa Process for producing Aliskiren
CN101913998A (zh) * 2010-07-06 2010-12-15 上海朴颐化学科技有限公司 4-溴-2-(3-甲氧基丙氧基)-苯甲醚的制备方法
WO2012034065A1 (en) 2010-09-09 2012-03-15 Teva Pharmaceutical Industries Ltd. Aliskiren intermediates and a process for analyzing the purity of aliskiren
DK2630118T3 (en) 2010-10-19 2015-02-09 Mylan Lab Ltd SYNTHESIS OF aliskiren
CN102001920B (zh) 2010-11-09 2013-05-15 常州制药厂有限公司 一种药物中间体的制备方法
CN102161627A (zh) * 2011-02-24 2011-08-24 中国药科大学 ω-(N取代-氨基烷基)辛酰胺
EP2551260A1 (en) 2011-07-28 2013-01-30 Chemo Ibérica, S.A. Chemical process for opening ring compounds
CN102942477B (zh) * 2011-08-14 2015-12-02 浙江华海药业股份有限公司 辛烯酸衍生物及其制备方法
CN102351734B (zh) * 2011-09-05 2014-02-26 浙江普洛医药科技有限公司 一种阿利克仑的制备方法
WO2013045505A1 (en) 2011-09-28 2013-04-04 Novartis Ag Biomarkers for raas combination therapy
US8703976B2 (en) * 2011-10-02 2014-04-22 Milan Soukup Manufacturing process for 8-aryloctanoic acids such as Aliskiren
WO2013061224A1 (en) 2011-10-25 2013-05-02 Jubilant Life Sciences Limited Process for the preparation of aliskiren
WO2013118138A1 (en) 2011-12-13 2013-08-15 Laboratories Ltd Mylan Novel process for the preparation of renin inhibitors
CN103172533B (zh) * 2011-12-20 2016-05-04 博瑞生物医药（苏州）股份有限公司 一种阿利克仑半富马酸盐的新晶型及其制备方法和用途
CN103204834A (zh) * 2012-01-11 2013-07-17 南京欧信医药技术有限公司 阿利克伦中间体及其制备方法和应用
WO2013121443A1 (en) 2012-02-17 2013-08-22 Mylan Laboratories Ltd. An improved process for the preparation of aliskiren
WO2013124868A2 (en) 2012-02-21 2013-08-29 Mylan Laboratories Limited Solid form of aliskiren intermediate
ITMI20120354A1 (it) * 2012-03-07 2013-09-08 Friulchem Spa Processo per la produzione di aliskirene
WO2013144979A1 (en) 2012-03-28 2013-10-03 Maylan Laboratories Ltd Process for the preparation of aliskiren
WO2013167715A1 (en) 2012-05-11 2013-11-14 Novartis Ag Dispensing device
WO2013171767A1 (en) 2012-05-18 2013-11-21 Mylan Laboratories Limited An improved process for the preparation of aliskiren
EP2810644A1 (en) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
CA2914899C (en) * 2013-06-27 2022-08-30 Dpx Holdings B.V. Preparation of grignard reagents using a fluidized bed
AU2019287551A1 (en) 2018-06-14 2021-01-28 Astrazeneca Uk Limited Methods for treatment of hypertension with an angiotensin II receptor blocker pharmaceutical composition
CN112679448B (zh) * 2020-12-31 2022-08-19 苏州昊帆生物股份有限公司 N-(2-氨基乙基)吗啉的制备方法
CN115340472B (zh) * 2022-09-19 2024-05-07 合肥工业大学 一种谷氨酸衍生物及其合成方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337207A (en) * 1980-09-04 1982-06-29 Regents Of The University Of California Biologically active catecholamine derivatives
US4729985A (en) * 1985-08-09 1988-03-08 Pfizer Inc. Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues
JPH02124884A (ja) * 1988-07-08 1990-05-14 Zhongguo Yixuekexueyuan Yaowo Yanjiusuo Ｎ―置換アミド誘導体
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities

Also Published As

Publication number Publication date
CY2208B1 (en) 2002-11-08
NO2009011I1 (no) 2009-06-02
US5559111A (en) 1996-09-24
DE122009000020I1 (de) 2009-08-06
CY2007027I1 (el) 2009-11-04
LU91373I2 (fr) 2007-12-31
CY2011015I2 (el) 2014-04-09
CZ97695A3 (en) 1995-11-15
KR950032037A (ko) 1995-12-20
NL300386I1 (nl) 2009-07-01
KR100353779B1 (ko) 2003-01-08
CN1550491A (zh) 2004-12-01
DE122007000071I2 (de) 2009-01-02
NO2011020I1 (no) 2011-09-26
NO2007011I1 (no) 2007-12-11
MY119161A (en) 2005-04-30
CA2147056C (en) 2005-10-25
AU699616B2 (en) 1998-12-10
ATE183997T1 (de) 1999-09-15
NO951441D0 (no) 1995-04-12
DK0678503T3 (da) 2000-03-20
NO310410B1 (no) 2001-07-02
DE59506707D1 (de) 1999-10-07
NL300296I1 (nl) 2007-12-03
HU226860B1 (en) 2009-12-28
CZ287935B6 (cs) 2001-03-14
ZA953051B (en) 1995-10-18
CY2009006I2 (el) 2010-07-28
NO2009011I2 (no) 2010-11-22
CN1266118C (zh) 2006-07-26
ES2137478T3 (es) 1999-12-16
CY2009006I1 (el) 2010-07-28
HK1070881A1 (en) 2005-06-30
ZA953050B (en) 1995-11-08
CA2147056A1 (en) 1995-10-19
DE122011100052I1 (de) 2012-01-19
HUT71701A (en) 1996-01-29
US5705658A (en) 1998-01-06
TW402582B (en) 2000-08-21
NL300296I2 (nl) 2008-02-01
CY2007027I2 (el) 2009-11-04
NZ270936A (en) 1997-06-24
US5646143A (en) 1997-07-08
FI951771A0 (fi) 1995-04-12
IL113403A0 (en) 1995-07-31
FI951771A (fi) 1995-10-19
FI118336B (fi) 2007-10-15
CN1153759C (zh) 2004-06-16
HU9501076D0 (en) 1995-06-28
HUT74074A (en) 1996-10-28
US5627182A (en) 1997-05-06
NO951441L (no) 1995-10-19
JPH0881430A (ja) 1996-03-26
DE122007000071I1 (de) 2008-01-31
ZA953052B (en) 1995-10-18
JP3240322B2 (ja) 2001-12-17
CY2011015I1 (el) 2014-04-09
LU91564I2 (fr) 2009-07-06
AU1642195A (en) 1995-10-26
BR1100656A (pt) 2000-06-06
GR3031997T3 (en) 2000-03-31
TW366341B (en) 1999-08-11
HU9501078D0 (en) 1995-06-28
RU95105970A (ru) 1997-01-10
NO2007011I2 (el) 2011-07-25
EP0678503B1 (de) 1999-09-01
EP0678503A1 (de) 1995-10-25
CN1117960A (zh) 1996-03-06
US5654445A (en) 1997-08-05

Similar Documents

Publication Publication Date Title
CA2147056C (en) Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides
US5641778A (en) Aromatically substituted ω-amino-alkanoic acid amides and alkanoic acid diamides
US4931591A (en) Novel 5-amino-4-hydroxyvaleryl derivatives
US20060154926A1 (en) Methods of treating alzheimer's disease using aryl alkanoic acid amides
JP3187535B2 (ja) 医薬的に活性なヒドラジン誘導体およびその製造方法
US5719141A (en) 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amide derivatives
AU626361B2 (en) Retroviral protease inhibitors
KR101755052B1 (ko) 락톤 및 락탐의 개환
IE911873A1 (en) Hiv protease inhibitors and processes for their preparation
CA2093109A1 (en) Morpholin- and thiomorpholin-4-ylamides
WO2003103652A1 (en) METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES
AU2013204947A1 (en) The ring opening of lactones and lactams

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
EXTF Application for patent extension filed
KB Patent renewed
EXTF Application for patent extension filed
EXTF Application for patent extension filed
KB Patent renewed
PEL Intention of commissioner to extend period of protection

Free format text: PRODUCT NAME: ALIS KIREN

Extension date: 20160612

EXTG Extension of patent term granted

Extension date: 20160612

EXTN Extension order renewed
EXTN Extension order renewed